Interferon-γ-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: A potential therapeutic target

American Journal of Respiratory Cell and Molecular Biology

Volumn 33, Issue 3, 2005, Pages 227-230

  El Hashemite, Nisreen ^a   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiomyolipoma; Interferon ; Lymphangioleiomyomatosis; Stats; Tuberous sclerosis

Indexed keywords

GAMMA INTERFERON; JANUS KINASE; RAPAMYCIN; SERINE; STAT PROTEIN; TYROSINE;

ANGIOMYOLIPOMA; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY TUMOR; LUNG DISEASE; LYMPHANGIOLEIOMYOMATOSIS; PATHOGENESIS; PREVALENCE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS;

ANGIOMYOLIPOMA; ANIMALS; DNA-BINDING PROTEINS; HUMANS; INTERFERON TYPE II; JANUS KINASE 1; JANUS KINASE 2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MICE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 24344479933     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2005-0152RC     Document Type: Article

References (19)

1. Hancock E, Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respir Med 2002;96:1-6.
2. Bernstein SM, Newell JD Jr, Adamczyk D, Mortenson RL, King TE Jr, Lynch DA. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med 1995;152:2138-2143.
3. Sullivan EJ. Lymphangioleiomyomatosis. Chest 1998;114:1689-1703.
4. Gomez M, Sampson J, Whitemore V. The tuberous sclerosis complex, 3rd ed. New York: Oxford University Press; 1999.
5. Hajdu SI, Foote FW Jr. Angiomyolipoma of the kidney: report of 27 cases and review of the literature. J Urol 1969;102:396-401.
6. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet 2000;107:97-114.
7. Niida Y, Stemmer-Rachamimov AO, Logrip M, Tapon D, Perez R, Kwiatkowski DJ, Sims K, MacCollin M, Louis DN, Ramesh V. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 2001;69:493-503.
8. Castro M, Shepherd C, Gomez M, Lie J, Ryu J. Pulmonary Tuberous Sclerosis. Chest 1995;107:189-195.
9. Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, McCormack FX. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001;164:661-668.
10. Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechtle J, Brooks PG, Hedin CJ, Hunsberger S, Kristof AS. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001;164:669-671.
11. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002;11:525-534.
12. El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003;36:1348-1349.
13. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 2002;277:30958-30967.
14. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated down-stream signaling. Proc Natl Acad Sci USA 2002;99:13571-13576.
15. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-5650.
16. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res 2004;64:3436-3443.
17. Ramana CV, Gil MP, Schreiber RD, Stark GR. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 2002;23:96-101.
18. Onda H, Crino PB, Zhang H, Murphey RD, Rastelli L, Gould Rothberg BE, Kwiatkowski DJ. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci 2002;21:561-574.
19. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El Hashemite N, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-g in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005;42:213-227.